119 completed, 50 unknown, 33 recruiting, 17 terminated. 127 Phase 2, 67 Phase 3, 63 Phase 1, 18 Phase 4, 10 Not applicable.
Follow Idarubicin: new trials by email Literature Review of Idarubicin trials Research Report on Idarubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-11-02 |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 300 | 2026-04-30 | 2026-03-25 |
| VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF - AML (Acute Myeloid Leukemia) | Phase 2 | Recruiting | Beijing 302 Hospital | 48 | 2026-04-15 | 2026-04-07 |
| Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Mitoxantrone Hydrochloride Liposome, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 204 | 2026-03-10 | 2026-03-20 |
| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) Bleximenib, Cytarabine, Daunorubicin or Idarubicin - Acute Myeloid Leukemia | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 875 | 2026-03-01 | 2026-11-06 |
| Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 102 | 2025-12-12 | 2026-10-20 |
| UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C) - Acute Myeloid Leukemia, Pediatric AML | Early Phase 1 | Recruiting | Baylor College of Medicine | 36 | 2025-10-22 | 2026-08-24 |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2025-09-26 | 2026-07-20 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients Daunorubicin/Idarubicin, Cytarabine, Azacitidine - AML, Adult | Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 228 | 2025-08-31 | 2026-10-26 |
| The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). - AML (Acute Myelogenous Leukemia), Down Syndrome (DS) | Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 100 | 2025-07-24 | 2025-11-20 |
| HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML daunorubicin, Venetoclax, cytarabine - AML | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 41 | 2025-01-21 | 2026-05-13 |
| Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 cytarabine, daunorubicin, idarubicin - AML, RUNX1-RUNX1T1 Fusion Protein Expression | Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 284 | 2025-01-10 | 2026-08-07 |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML Quizartinib, Placebo, Chemotherapy - Leukemia | Phase 3 | Active not recruiting | Daiichi Sankyo | 700 | 2024-11-19 | 2026-07-02 |
| Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia sonrotoclax, idarubicin/daunorubicin, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Shanghai Jiao Tong University School of Medicine | 47 | 2024-10-30 | 2026-04-30 |
| Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML Chidamide, Venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 240 | 2024-08-21 | 2025-11-17 |
| Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab - Lung Cancer, Surgery | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 90 | 2024-07-01 | 2024-07-09 |
| Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab - Hepatic Cancer, Surgery | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 90 | 2024-07-01 | 2024-07-09 |
| Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab - Liver Cancer, Antibody | Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 90 | 2024-06-10 | 2024-07-01 |
| MRD-positive AML Clinical Study Ivosidenib, Gilteritinib, Venetoclax - AML, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 537 | 2024-05-11 | 2026-08-10 |
Showing 20 of 247. Sign in to see all of them.
Leukemia, Myeloid, Acute (151) · Leukemia (67) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (29) · Leukemia, Monocytic, Acute (26) · Leukemia, Myelomonocytic, Acute (26) · Myelodysplastic Syndromes (25) · Leukemia, Erythroblastic, Acute (23) · Congenital Abnormalities (22) · Leukemia, Megakaryoblastic, Acute (22) · Leukemia, Promyelocytic, Acute (13) · Anemia, Refractory, with Excess of Blasts (12) · Leukemia, Myelomonocytic, Chronic (12) · Recurrence (10) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Myeloproliferative Disorders (8)
M.D. Anderson Cancer Center (23) · European Organisation for Research and Treatment of Cancer - EORTC (12) · National Cancer Institute (NCI) (11) · PETHEMA Foundation (11) · Fred Hutchinson Cancer Center (9) · Institute of Hematology & Blood Diseases Hospital, China (8) · Children's Oncology Group (7) · St. Jude Children's Research Hospital (6) · Goethe University (5) · Massachusetts General Hospital (5) · Nanfang Hospital, Southern Medical University (5) · University of Ulm (5) · Arog Pharmaceuticals, Inc. (4) · Memorial Sloan Kettering Cancer Center (4) · Second Affiliated Hospital of Guangzhou Medical University (4)
United States (113) · Germany (45) · China (39) · France (35) · Italy (26) · Spain (24) · Belgium (18) · United Kingdom (18) · Canada (17) · Netherlands (17) · Australia (15) · Austria (15) · South Korea (13) · Switzerland (11) · Poland (10)
Farhad Ravandi-Kashani, MD (4) · Zhenfeng Zhang, MD, PhD (4) · Dieter Hoelzer, MD,PhD (3) · Sergio Amadori, MD (3) · Theo De Witte, MD, PhD (3) · Alan K. Burnett, MD, FRCP (2) · Amir Fathi, MD (2) · Anthony S. Stein, MD (2) · Franco Mandelli, MD (2) · Guillermo Garcia-Manero (2) · Hiroto Inaba, MD, PhD (2) · Jorge Cortes (2)
PMID 29702001, PMID 19144982, PMID 19602710, PMID 21343560, PMID 22442346, PMID 22493293, PMID 22512017, PMID 22965967, PMID 23024237, PMID 27561722, PMID 28751559, PMID 29427728, PMID 36892565, PMID 42477805, PMID 10499612, PMID 11426549, PMID 11468154, PMID 11981766, PMID 12049862, PMID 12091661, PMID 12540794, PMID 12627513, PMID 15087948, PMID 15154634, PMID 15339678, PMID 15761020, PMID 16136166, PMID 16197446, PMID 16333838, PMID 16932345, PMID 17315155, PMID 17339189, PMID 18039957, PMID 18083847, PMID 18182574, PMID 18286501, PMID 18398750, PMID 18648353, PMID 18802149, PMID 19059939, PMID 19242495, PMID 19291085, PMID 19304957, PMID 19688832, PMID 19805689, PMID 19826132, PMID 20038732, PMID 20056794, PMID 20393132, PMID 20413658
2015 (3), 2017 (3), P30CA015704 (3), P30CA016672 (3), U10CA098543 (3), 2008 (2), 2018 (2), 2023 (2), N01CM62202 (2), P30CA033572 (2), U10CA032102 (2), 2004 (1), 2014 (1), 2016 (1), 2025 (1)